UK markets close in 3 hours 5 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3000-0.3800 (-22.62%)
At close: 04:00PM EST
1.2685 -0.03 (-2.42%)
Pre-market: 08:24AM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.6800
Open1.6800
Bid1.2600 x 4000
Ask1.2600 x 1300
Day's range1.2800 - 1.7000
52-week range0.2570 - 11.5200
Volume5,028,483
Avg. volume9,785,038
Market cap14.392M
Beta (5Y monthly)3.64
PE ratio (TTM)N/A
EPS (TTM)-8.0000
Earnings date11 Dec 2023 - 13 Dec 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

  • PR Newswire

    RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

    RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years' market exclusivity for Talicia3 under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board. This grant is on top of three years' exclusivity granted for the approval of Talicia under section 505(b)(2). Tal

  • PR Newswire

    RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") to transfer the listing of the American Depositary Shares ("ADSs") to the Nasdaq Capital Market. The ADSs will be transferred to the Nasdaq Capital Market at the opening of business on November 15, 2023.